Home/Pipeline/Lead MDC Program

Lead MDC Program

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Cellis

About Cellis

Cellis is a private, pre-clinical stage biotech founded in 2017, developing a novel macrophage-based cell therapy platform for solid tumors. Its proprietary Macrophage Drug Conjugate (MDC) technology leverages a biological mechanism called TRAIN to enable targeted drug delivery into cancer cells, aiming to kill tumors and remodel the immunosuppressive tumor microenvironment. The company is preparing for first-in-human clinical trials targeted for Q1 2026 and has secured European Union co-financing alongside private funding.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed